Zomedica Pharmaceuticals Corp. (NYSE:ZOM) went up by 1.45% from its latest closing price when compared to the 1-year high value of $0.67 and move down -318.75%, while ZOM stocks collected +6.46% of gains with the last five trading sessions. Press Release reported on 02/26/20 that Zomedica Pharmaceuticals Corp. Announces Year End 2019 Financial Results
Zomedica Pharmaceuticals Corp. (NYSE:ZOM) Worth an Investment?
Zomedica Pharmaceuticals Corp. (NYSE: ZOM) The 36 Months beta value for ZOM stocks is at 0.61, while of the analysts out of 0 who provided ratings for Zomedica Pharmaceuticals Corp. stocks as a “buy” while as overweight, rated it as hold and as sell. The average price we get from analysts is $0.65 which is -$0.16 below current price. ZOM currently has a short float of 0.05% and public float of 66.50M with average trading volume of 7.21M shares.
ZOM Market Performance
ZOM stocks went up by 6.42% for the week, with the monthly drop of -34.10% and a quarterly performance of -50.72%, while its annual performance rate touched -48.52%. The simple moving average for the period of the last 20 days is -19.06% for ZOM stocks with the simple moving average of -43.73% for the last 200 days.
ZOM Stocks -26.04% Far from 50 Day Moving Average
After a stumble in the market that brought ZOM to its low price for the period of the last 52 weeks, Zomedica Pharmaceuticals Corp. was unable to take a rebound, for now settling with -75.41% of loss for the given period.
The stock volatility was left at 26.67%, however, within the period of a single month, the volatility rate increased by 17.87%, while the shares sank at the distance of -18.86% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -45.25% lower at the present time.
In the course of the last 5 trading sessions, ZOM went up by +6.46%, which changed the moving average for the period of 200 days to the total of -45.07% of losses for the stock in comparison to the 20-day moving average settled at $0.2016. In addition, Zomedica Pharmaceuticals Corp. saw -50.23% in overturn over the period of a single year with a tendency to cut further losses.